Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Evogene Ltd. (NASDAQ: EVGN) announced that President and CEO Ofer Haviv will present at the Jefferies Virtual 2020 Industrials Conference on August 6, 2020, at 8:00 am EST. The presentation will highlight the company's innovative Computational Predictive Biology (CPB) platform, focusing on ag-chemicals and ag-biologicals. Investors interested in a meeting can contact Evogene's Investor Relations team. Evogene is dedicated to enhancing life-science product development through its unique technology and aims to address various market segments, including agriculture and human health.
Evogene Ltd. (NASDAQ: EVGN) will release its second-quarter 2020 financial results on August 5, 2020. The company's management will discuss these results in a conference call at 09:00 AM ET and 16:00 Israel time. The call can be accessed via telephone or live webcast on their website. Evogene focuses on computational biology to develop life-science products and employs its Computational Predictive Biology platform across various sectors including human health and agriculture.